Resumen

AGRAMONTE LLANES, Olga et al. Use of the recombinant activated factor VII in non-hemophilic patients in Cuba. Rev Cubana Hematol Inmunol Hemoter [online]. 2008, vol.24, n.3, pp. 0-0. ISSN 1561-2996.

The recombinant activated factor VII (rFVIIa, NovoSeven®) has been used in the treatment of bleedings in hemophilic patients with inhibitors. It has also been used for treating uncontrolled bleedings associated with trauma or surgery. The treatment with rFVIIa in 7 non-hemophilic patients with a wide range of hemorrhagic events is described: 3 that underwent liver transplant and presented posttransplant without response to the conventional treatment; 1 with severe medullary aplasia and retinal hemorrhage; 1 with Rendú-Osler-Weber's disease that had severe gastrointestinal bleeding; and 1 patient with cutaneous and pulmonary hemorrhagic manifestations due to a viral disease. The dose of rFVIIa used was between 90 and 100 µg/kg of weight, both for the prophylactic and therapeutic treatment. The activated rFVII reached an effective hemostasis in all cases. We consider that the activated FVII may be applied when the combination of hemoderivatives and the surgical advances have failed in the control of bleedings endangering life

Palabras clave : rFVIIa; non-hemophilic patients; liver transplant; Rendú Osler Weber's disease.